[email protected]
CDI - Contrive Datum Insights
Press ReleaseMedical Devices

Radiation Oncology Market Projected at USD 18.7 billion by 2034 on 7.48% Annual Growth

Carbon Ion Therapy is the fastest-growing line at 13.58%; North America is the largest region at 41% of 2025 revenue.

PUNE, INDIA — 18 NOVEMBER 2026 — CONTRIVE DATUM INSIGHTS

Market reaches USD 18.7 billion by 2034, up from USD 9.8 billion in 2025, at a 7.48% CAGR.

41% of 2025 revenue (USD 4.018 billion) is generated in North America.

Carbon Ion Therapy is the fastest-growing line at 13.58% annually.

External Beam Radiation Therapy leads treatment modality with 72% of 2025 revenue.

The global radiation oncology market was valued at USD 9.8 billion in 2025. The market is projected to grow from USD 10.5 billion in 2026 to USD 18.7 billion by 2034, exhibiting a compound annual growth rate of 7.48% during the forecast period. Contrive Datum Insights presents this information in its report titled "Radiation Oncology Market Size, Share & Industry Analysis, By Treatment modality (External Beam Radiation Therapy, Proton Therapy, Carbon Ion Therapy, Brachytherapy, Systemic Radioisotope Therapy, Intraoperative Radiotherapy), Technique (3D Conformal Radiotherapy, Intensity-Modulated Radiotherapy, Volumetric Modulated Arc Therapy, Image-Guided Radiotherapy, Stereotactic Radiotherapy, Adaptive Radiotherapy), Product and service offering (Treatment Delivery Systems, Treatment Planning Software, Oncology Information Systems, Patient Positioning and Immobilization, Quality Assurance and Dosimetry, Radioisotopes and Sealed Sources, Installation, Maintenance and Upgrade Services), Cancer type (Prostate Cancer, Breast Cancer, Lung Cancer, Head and Neck Cancer, Colorectal Cancer, Brain and Central Nervous System Tumors, Gynecological Cancer, Other Cancers), Treatment intent (Curative, Adjuvant, Neoadjuvant, Palliative), Fractionation regimen (Conventional Fractionation, Moderate Hypofractionation, Ultra-Hypofractionation, Hyperfractionation, Accelerated Fractionation), End user (Hospitals, Independent Radiotherapy Centers, Cancer Research Institutes, Ambulatory Oncology Clinics), Patient age group (Pediatric, Adult, Geriatric), Procurement model (Outright Purchase, Leasing and Equipment-as-a-Service, Per-Procedure or Managed Service Contracts, Public Tender and Government Procurement), and Regional Forecast, 2026-2034".

Radiation oncology covers the equipment, software, isotopes and services used to treat cancer with ionising radiation, whether delivered from outside the body, placed inside it, or given as a radioactive drug. It spans linear accelerators, particle therapy systems, brachytherapy sources, treatment planning and information systems, patient positioning and quality assurance tools, and the service contracts that keep them running. Buyers are hospitals, independent radiotherapy centers, cancer research institutes and ambulatory oncology clinics, with public tenders and leasing providers shaping many purchases.

Rising cancer incidence and ageing populations

Rising cancer incidence and ageing populations is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 7.48% a year, the treatment modality lines exposed to it move fastest: Carbon Ion Therapy compounds at 13.58%, taking its share of revenue from 1.5% to 2.5% and its value from USD 0.147 billion to USD 0.468 billion.

Where the forecast could be beaten: faster uptake of adaptive and radioligand therapy, earlier financing of proton projects, and reimbursement that supports shorter courses without cutting per-course payment. The study puts that case at USD 20.9 billion in 2034, against USD 18.7 billion in the base.

Against that, delayed capital budgets and proton financing, slower radioligand scale-up because of isotope supply limits, and reimbursement cuts that lower revenue per course. On that reading 2034 revenue stops at USD 16.1 billion. The weight of the problem sits in External Beam Radiation Therapy: 72% of 2025 revenue growing at 5.7%, well under the market's 7.48%.

Where the Competition Actually Sits

The treatment modality axis, not the regional one, is what divides the field. External Beam Radiation Therapy is the volume position, 72% of 2025 revenue at USD 7.056 billion, holding 62% through 2034, and it is defended by scale. Carbon Ion Therapy is the growth position at 13.58%, and it is open. Strength in one does not carry into the other.

Further Report Findings

SegmentLed 2025 byShare & valueFastest-growing
TechniqueIntensity-Modulated Radiotherapy24% · USD 2.352 billionAdaptive Radiotherapy 19.48%
Product and service offeringTreatment Delivery Systems38% · USD 3.724 billionRadioisotopes and Sealed Sources 12.4%
Cancer typeOther Cancers21% · USD 2.058 billionBrain and Central Nervous System Tumors 8.86%
Treatment intentCurative48% · USD 4.704 billionNeoadjuvant 10.14%
Fractionation regimenConventional Fractionation40% · USD 3.92 billionUltra-Hypofractionation 15.1%
End userHospitals72% · USD 7.056 billionIndependent Radiotherapy Centers 10.49%
Patient age groupGeriatric60% · USD 5.88 billion—
Procurement modelOutright Purchase44% · USD 4.312 billionLeasing and Equipment-as-a-Service 13.97%
  • Regionally, the lead sits with North America: 41% of 2025 global revenue, USD 4.018 billion rising to USD 6.732 billion in 2034.
  • Asia Pacific takes a rising share of global revenue over the forecast period, from 24% in 2025 to 31% in 2034, with revenue growing from USD 2.352 billion to USD 5.797 billion.
  • Middle East and Africa remains the smallest region throughout, at 4.5% of 2025 revenue and 4.7% by 2034.
  • By treatment modality, the largest line in 2025 was External Beam Radiation Therapy, at 72% of revenue and USD 7.056 billion.
  • Carbon Ion Therapy is projected to grow at 13.58% over the forecast period, the fastest of any treatment modality line.
  • The United States is the largest single country market at USD 3.6 billion in 2025, 36.73% of global revenue.

Every year from 2020 to 2034 is reported, with revenue and growth for each line across nine axes: by treatment modality, and by technique, product and service offering, cancer type, treatment intent, fractionation regimen, end user, patient age group and procurement model. The headline total carries bear, base and bull cases at USD 16.1 billion and USD 20.9 billion by 2034. The study also breaks out all five regions to country level, sets out the competitive landscape, and documents the method behind every estimate. Available as a PDF, with a free sample on request.

Regions Covered
North AmericaEuropeAsia PacificLatin AmericaMiddle East and Africa
About Contrive Datum Insights

Contrive Datum Insights is a global market intelligence and consulting firm working across investment, information technology, healthcare and manufacturing markets. Every market we publish is sized twice — once top-down from the leading players and once bottom-up from the addressable base — and validated by primary interview. More about CDI.

Media contact
[email protected]
Asia Pacific
Kunjir Shyama Prestine, Sr. no. 174/1
Jagtap Diary Road, Pimple Saudagar
Pune 411017, India
+91 983 481 6757
United States
21C2 Lakeshore Dr.
Farmington, CT 06032
United States
+1 215 297 4078